OncoMatch/Clinical Trials/NCT06617481
PET Scan Study to Detect Prostate Cancer in Patients with Early PSA Recurrence
Is NCT06617481 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies 18F-rhPSMA-7.3 (Posluma) for prostate cancer (post prostatectomy).
Treatment: 18F-rhPSMA-7.3 (Posluma) — Flotufolastat F-18, sold under the brand name Posluma, is a radioactive diagnostic agent for use with positron emission tomography (PET) imaging for prostate cancer. The research is being done to study the capability of 18F-rhPSMA-7.3 (flotufolastat F-18) PET scan to detect prostate cancer when there are very low levels of Prostate-Specific Antigen (PSA) following previous radical prostatectomy surgery.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Prostate Cancer
Demographics
Prior therapy
Must have received: radical prostatectomy — curative intent
prior curative intent radical prostatectomy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- AdventHealth · Orlando, Florida
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06617481 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received radical prostatectomy.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages